Immune therapy of melanoma: Overview of therapeutic vaccines. Issue 9 (31st January 2019)

• Record Type: Journal Article
• Authors: Payandeh, Zahra; Yarahmadi, Maral; Nariman‐Saleh‐Fam, Ziba; Tarhriz, Vahideh; Islami, Maryam; Aghdam, Abdolreza Mehdinavaz; Eyvazi, Shirin
• Is Part Of: Journal of cellular physiology. Volume 234:Issue 9(2019:Sep.)
• Page Start: 14612
• Page End: 14621
• Publication Date: 2019-01-31
• Subjects: cancer immunotherapy -- immune checkpoint receptors -- melanoma -- mRNA‐based dendritic cell vaccines; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.28181
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract: Melanoma is the most serious type of skin cancer which develops from the occurrence of genetic mutations in the melanocytes. Based on the features of melanoma tumors such as location, genetic profile and stage, there are several therapeutic strategies including surgery, chemotherapy, and radiotherapy. However, because of the appearance resistance mechanisms, the efficiency of these treatments strategies may be reduced. It has been demonstrated that therapeutic monoclonal antibodies can improve the efficiency of melanoma therapies. Recently, several mAbs, such as nivolumab, pembrolizumab, and ipilimumab, were approved for the immunotherapy of melanoma. The antibodies inhibit immune checkpoint receptors such as CTL4 and pd‐1. Another therapeutic strategy for the treatment of melanoma is cancer vaccines, which improve clinical outcomes in patients. The combination therapy using antibodies and gene vaccine give us a new perspective in the treatment of melanoma patients. Herein, we present the recent progressions in the melanoma immunotherapy, especially dendritic cells mRNA vaccines by reviewing recent literature. Abstract : Melanoma is the most serious type of skin cancer. Recently, several mAbs such as nivolumab, pembrolizumab, and ipilimumab were approved for the immunotherapy of melanoma. The combination therapy using antibodies and gene vaccine gives us a new perspective in the treatment of melanoma patients.